Search

Search Constraints

You searched for: Author/Creator Coco, B.

Search Results

1. High efficacy of direct‐acting anti‐viral agents in hepatitis C virus‐infected cirrhotic patients with successfully treated hepatocellular carcinoma. Issue 12 (3rd May 2018)

2. AF.96 MODELING HEPATOCELLULAR CARCINOMA CELLS DYNAMICS BY SEROLOGICAL AND IMAGING BIOMARKERS TO EXPLAIN COMPLETE RESPONSE TO SORAFENIB. (September 2021)

3. AF.88 THREE HBSAG KINETIC PROFILES IN HBEAG NEGATIVE INFECTION AND CHRONIC HEPATITIS ARE ASSOCIATED WITH DIFFERENT CHANCES OF HBSAG CLEARANCE. (September 2021)

4. AF.89 CHANGING DEMOGRAPHIC-CLINIC-PATHOLOGIC PROFILES OF NEWLY DIAGNOSED CARRIERS OF CHRONIC HEPATITIS B VIRUS INFECTION ACROSS TWO DECADES: A SINGLE ITALIAN REFERENCE CENTER REPORT. (September 2021)

5. AF.84 BIOIMAGING, BIOCHEMICAL AND GENETIC MARKERS TO STRATIFY PATIENTS WITH METABOLIC ASSOCIATED FATTY LIVER DISEASE (MAFLD) IN CLINICAL PRACTICE: A SINGLE CENTER COHORT STUDY. (September 2021)

6. OC.04.9 A SINGLE CENTER, LARGE LONG TERM COHORT STUDY OF THE RELATIONS BETWEEN MUTATIONS IN BASIC-CORE-PROMOTER AND PRE-C REGIONS OF HEPATITIS B VIRUS DNA AND CLINICPATHOLOGIC OUTCOME OF HBEAG-NEGATIVE/ANTI-HBEPOSITIVE PHASE. (September 2021)

7. A multicentre prospective study response to treatment in genotype 3 and 1b infected patients with sickest liver cirrhosis: SVR 4 is not a reliable measure. (8th October 2016)

8. Cancer cells and tumor vasculature dynamics analyzed by bio-mathematical modeling in HCC patients with different response to TKIs, TACE and TARE. (October 2022)

9. In HCV infected patients with cirrhosis Squamous Cell Carcinoma Antigen (SCCA)-IgM levels may contribute to identify the individual risk of HCC development after antiviral therapy. Issue 1 (16th February 2017)

10. Comparative antiviral efficacy with higher ALT normalization of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in HBeAg-negative, genotype D chronic hepatitis B. Issue 1 (16th February 2017)